Huadong Medicine vs Cencora: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Huadong Medicine Co Ltd (000963.CS)

Q3 202620 Jul – 27 Aug 2026

▲2▼1

Procurement loss and profit dip offset aesthetics and FDA wins

Procurement loss threatens core revenue Huadong lost bids for four products, including core indobufen tablets, with 2025 sales of 4.634 billion yuan — 10.62% of total revenue. Losing hospital access will likely cut future sales, a real drag on the stock.
This is the biggest negative force this period, directly threatening a large chunk of revenue.
Aesthetic products gain China and EU approvals Huadong's subsidiary won EU CE certification for an injectable aesthetic product and China approval for MaiLi Precise, the first injectable for under-eye hollows. These open new markets and support future growth, though near-term financial impact is small.
New product approvals are a positive growth driver that can lift investor sentiment.
FDA fast track for innovative cancer drug HDM2005, a first-in-class ROR1-targeting ADC for mantle cell lymphoma, received FDA Fast Track designation. This speeds up development and review, boosting the company's innovative drug story and long-term potential.
A regulatory win for a novel cancer drug adds credibility and future revenue potential.
Interim profit up but quarterly slowdown First-half net profit rose 2.53% to 1.861 billion yuan, with a 3.5 yuan per 10 shares dividend. But second-quarter profit fell 14% from the first quarter, and margins weakened, so the market may worry about momentum.
The earnings report is the key financial update, showing both stability and a concerning quarterly decline.

August 202620 Jul – 27 Aug 2026

▲2▼1

Procurement loss and profit dip offset aesthetics and FDA wins

Procurement loss threatens core revenue Huadong lost bids for four products, including core indobufen tablets, with 2025 sales of 4.634 billion yuan — 10.62% of total revenue. Losing hospital access will likely cut future sales, a real drag on the stock.
This is the biggest negative force this period, directly threatening a large chunk of revenue.
Aesthetic products gain China and EU approvals Huadong's subsidiary won EU CE certification for an injectable aesthetic product and China approval for MaiLi Precise, the first injectable for under-eye hollows. These open new markets and support future growth, though near-term financial impact is small.
New product approvals are a positive growth driver that can lift investor sentiment.
FDA fast track for innovative cancer drug HDM2005, a first-in-class ROR1-targeting ADC for mantle cell lymphoma, received FDA Fast Track designation. This speeds up development and review, boosting the company's innovative drug story and long-term potential.
A regulatory win for a novel cancer drug adds credibility and future revenue potential.
Interim profit up but quarterly slowdown First-half net profit rose 2.53% to 1.861 billion yuan, with a 3.5 yuan per 10 shares dividend. But second-quarter profit fell 14% from the first quarter, and margins weakened, so the market may worry about momentum.
The earnings report is the key financial update, showing both stability and a concerning quarterly decline.

Latest20 Jul – 27 Aug 2026

▲2▼1

Procurement loss and profit dip offset aesthetics and FDA wins

Procurement loss threatens core revenue Huadong lost bids for four products, including core indobufen tablets, with 2025 sales of 4.634 billion yuan — 10.62% of total revenue. Losing hospital access will likely cut future sales, a real drag on the stock.
This is the biggest negative force this period, directly threatening a large chunk of revenue.
Aesthetic products gain China and EU approvals Huadong's subsidiary won EU CE certification for an injectable aesthetic product and China approval for MaiLi Precise, the first injectable for under-eye hollows. These open new markets and support future growth, though near-term financial impact is small.
New product approvals are a positive growth driver that can lift investor sentiment.
FDA fast track for innovative cancer drug HDM2005, a first-in-class ROR1-targeting ADC for mantle cell lymphoma, received FDA Fast Track designation. This speeds up development and review, boosting the company's innovative drug story and long-term potential.
A regulatory win for a novel cancer drug adds credibility and future revenue potential.
Interim profit up but quarterly slowdown First-half net profit rose 2.53% to 1.861 billion yuan, with a 3.5 yuan per 10 shares dividend. But second-quarter profit fell 14% from the first quarter, and margins weakened, so the market may worry about momentum.
The earnings report is the key financial update, showing both stability and a concerning quarterly decline.

Cencora Inc. (COR)

Q3 202613 Jul – 19 Sep 2026

▲3

Cencora lifts guidance on specialty drug strength, adds buyback and AI push

Profit outlook raised again on specialty drugs Cencora beat profit estimates and raised its full-year earnings guidance, with adjusted operating income up 17% as specialty and cancer-care businesses grew. Higher expected profits make the shares worth more to investors, which is why the stock rose.
The repeated guidance raise and profit beat are the core force lifting COR.
$1 billion buyback finished early Cencora bought back $1 billion of its own stock in the quarter, finishing a program it had planned to spread through 2026, and kept paying its dividend. Fewer shares outstanding lifts earnings per share and signals confidence, supporting the price.
Buybacks directly shrink share count and support the stock price.
New cell and gene therapy service for hospitals Cencora launched a service helping hospitals set up cell and gene therapy programs, a fast-growing area where most hospital pharmacy leaders say they are unprepared. This opens a new source of demand and fees, supporting future revenue growth.
It is a new business line that expands COR's addressable market.
AI speeds decisions, but costs and thin GLP-1 margins bite Cencora says AI roughly halves the time for some treatment decisions, a plus for its technology story. But GLP-1 drugs carry lower margins, interest costs jumped 72% after the OneOncology deal, and it lost an oncology customer, weighing on results.
It gives the fair counterweight: real positives alongside margin and cost pressures.

August 202613 Jul – 19 Sep 2026

▲3

Cencora lifts guidance on specialty drug strength, adds buyback and AI push

Profit outlook raised again on specialty drugs Cencora beat profit estimates and raised its full-year earnings guidance, with adjusted operating income up 17% as specialty and cancer-care businesses grew. Higher expected profits make the shares worth more to investors, which is why the stock rose.
The repeated guidance raise and profit beat are the core force lifting COR.
$1 billion buyback finished early Cencora bought back $1 billion of its own stock in the quarter, finishing a program it had planned to spread through 2026, and kept paying its dividend. Fewer shares outstanding lifts earnings per share and signals confidence, supporting the price.
Buybacks directly shrink share count and support the stock price.
New cell and gene therapy service for hospitals Cencora launched a service helping hospitals set up cell and gene therapy programs, a fast-growing area where most hospital pharmacy leaders say they are unprepared. This opens a new source of demand and fees, supporting future revenue growth.
It is a new business line that expands COR's addressable market.
AI speeds decisions, but costs and thin GLP-1 margins bite Cencora says AI roughly halves the time for some treatment decisions, a plus for its technology story. But GLP-1 drugs carry lower margins, interest costs jumped 72% after the OneOncology deal, and it lost an oncology customer, weighing on results.
It gives the fair counterweight: real positives alongside margin and cost pressures.

Latest13 Jul – 19 Sep 2026

▲3

Cencora lifts guidance on specialty drug strength, adds buyback and AI push

Profit outlook raised again on specialty drugs Cencora beat profit estimates and raised its full-year earnings guidance, with adjusted operating income up 17% as specialty and cancer-care businesses grew. Higher expected profits make the shares worth more to investors, which is why the stock rose.
The repeated guidance raise and profit beat are the core force lifting COR.
$1 billion buyback finished early Cencora bought back $1 billion of its own stock in the quarter, finishing a program it had planned to spread through 2026, and kept paying its dividend. Fewer shares outstanding lifts earnings per share and signals confidence, supporting the price.
Buybacks directly shrink share count and support the stock price.
New cell and gene therapy service for hospitals Cencora launched a service helping hospitals set up cell and gene therapy programs, a fast-growing area where most hospital pharmacy leaders say they are unprepared. This opens a new source of demand and fees, supporting future revenue growth.
It is a new business line that expands COR's addressable market.
AI speeds decisions, but costs and thin GLP-1 margins bite Cencora says AI roughly halves the time for some treatment decisions, a plus for its technology story. But GLP-1 drugs carry lower margins, interest costs jumped 72% after the OneOncology deal, and it lost an oncology customer, weighing on results.
It gives the fair counterweight: real positives alongside margin and cost pressures.